Stockscreener 앱 받기
1.24
0.00%
0.00
시장 영업 전:
1.24
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to earnings forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO) - TradingView
Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to book forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Telomir Pharmaceuticals, Inc. develops Telomir-Zn to target intracellular metal balance in cancer cells - Traders Union
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals to advance Telomir-Zn into clinical development for triple-negative breast cancer - Traders Union
Telomir Pharmaceuticals, Inc.: Telomir-Zn reverses insulin resistance in 14 days in new study - Traders Union
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data - TipRanks
Telomir publishes preclinical data on diabetes treatment candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Restores Insulin Sensitivity in Type 2 Diabetes Model – Minichart - Minichart
Telomir publishes preclinical data on diabetes treatment candidate - Investing.com
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Experimental drug candidate reversed insulin resistance in 14 days — in fish - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre‑Revenue Development StageSubscription Growth Report - newsline.com
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Despite Positive Stock Reaction - newsline.com
Telomir Pharmaceuticals, Inc. reveals promising anti-tumor impact with Telomir-Zn in prostate cancer study - Traders Union
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Cash Burn ConcernsConsensus Miss Rate - dars.gov.et
Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3 - Stock Titan
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com UK
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change - TipRanks
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Australia
Telomir PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026 - marketscreener.com
Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO - Stock Titan
Telomir Pharmaceuticals (TELO) Edges Lower Amid Consolidation Near SupportTrend Following Picks - newsline.com
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) - ChartMill
TELOTelomir Pharmaceuticals Inc Stock Price and Quote - Finviz
Telomir Pharmaceuticals (TELO) Edges Lower, Testing Support Levels Amid Low VolumeProfitability Factor - The Legal Advocate
TELO Q4 2025 Earnings: EPS Misses Estimates by 292% as Cash Burn Continues; No Revenue ReportedEPS Surprise History - newsline.com
Telomir Pharmaceuticals (TELO) Consolidates Near $1.29 as Support and Resistance Levels TightenATR Stop - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Significant EPS Miss Amid Pre-Clinical Stage OperationsNext Quarter Guidance - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue ChallengesCFO Commentary Report - The Legal Advocate
Telomir Pharmaceuticals Q4 2025 Earnings: Wider Than Expected Loss Highlights Clinical-Stage ChallengesAnnual Financial Report - newsline.com
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - ACCESS Newswire
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesReturn On Capital - The Legal Advocate
3.27%
0.61%
자본화:
|
볼륨(24시간):